Biogen Plans Regulatory Filing for Aducanumab in Alzheimer’s Disease Based on New Analysis of Larger Dataset from Phase 3 Studies
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- Wall St set for higher open as investors weigh Mideast negotiations
- Oil falls after US-Iran talks signal easing supply risks
- Intel soars after Trump says Apple agreed to work with chipmaker on US production
- Apple CEO warns price hikes 'unavoidable' as chip costs bite - WSJ
- Wall Street scrambles to lift Micron price targets ahead of earnings
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Companies to add 40 million barrels of oil to US SPR after Iran war ends, energy secretary says
- China makes small dent in deflation battle as supply-demand imbalance persists
- Sanuwave cuts Q2 2026 revenue guidance amid Ultramist sales pressure
Biogen (BIIB) PT Raised to $305 at Canaccord Genuity
October 23, 2019 5:14 AM EDTCanaccord Genuity analyst Sumant Kulkarni raised the price target on Biogen (NASDAQ: BIIB) to $305.00 (from $285.00) while maintaining a Hold rating.
... MoreBiogen (BIIB) PT Raised to $297 at BMO Capital
October 23, 2019 4:44 AM EDTBMO Capital analyst George Farmer raised the price target on Biogen (NASDAQ: BIIB) to $297.00 (from $250.00) while maintaining a Market Perform rating.
The analyst comments "After a failed futility analysis reported last March, new results from the Phase 3 trials, EMERGE and ENGAGE, now support... More
Biogen (BIIB) PT Raised to $310 at Jefferies
October 22, 2019 1:45 PM EDTJefferies analyst Michael Yee raised the price target on Biogen (NASDAQ: BIIB) to $310.00 (from $255.00) while maintaining a Hold rating.
stock pricing in renewed hopes againasks if M&A could be next... MoreBiogen (BIIB) News 'Somewhat Astonishing', Shares Could Trade Back Toward Low-$300s - RBC
October 22, 2019 7:32 AM EDTRBC Capital analyst Brian Abrahams weighed in on news Biogen (NASDAQ: BIIB) will pursue regulatory approval of aducanumab in Alzheimer's.
"We expect more clarity on BIIB's earnings call this morning but believe that given the multi-$B potential opportunity, we could see shares initially... More
Biogen (BIIB) Surges 18.5% Pre-Market After Announcing Plans to Pursue Regulatory Approval for Aducanumab in Alzheimer’s Disease
October 22, 2019 6:41 AM EDTBiogen (NASDAQ: BIIB) Surges 18.5% Pre-Market After Announcing Plans to Pursue Regulatory Approval for Aducanumab in Alzheimers Disease
... More